Recordati Industria Chimica e Farmaceutica (OTCMKTS:RCDTF) Hits New 12-Month Low – Time to Sell?

Recordati Industria Chimica e Farmaceutica S.p.A. (OTCMKTS:RCDTFGet Free Report)’s stock price reached a new 52-week low during trading on Friday . The company traded as low as $52.25 and last traded at $52.25, with a volume of 0 shares trading hands. The stock had previously closed at $52.25.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on RCDTF. Barclays raised shares of Recordati Industria Chimica e Farmaceutica to a “strong sell” rating in a research report on Tuesday. Royal Bank of Canada raised Recordati Industria Chimica e Farmaceutica to a “hold” rating in a research report on Monday, October 7th.

View Our Latest Research Report on RCDTF

Recordati Industria Chimica e Farmaceutica Stock Performance

The firm’s 50 day moving average price is $52.25 and its 200-day moving average price is $51.88. The firm has a market cap of $10.78 billion, a price-to-earnings ratio of 26.13 and a beta of 0.33. The company has a debt-to-equity ratio of 0.73, a current ratio of 1.36 and a quick ratio of 0.95.

Recordati Industria Chimica e Farmaceutica (OTCMKTS:RCDTFGet Free Report) last posted its quarterly earnings results on Tuesday, July 30th. The company reported $0.70 earnings per share (EPS) for the quarter. Recordati Industria Chimica e Farmaceutica had a net margin of 17.41% and a return on equity of 30.78%. The company had revenue of $622.00 million for the quarter.

About Recordati Industria Chimica e Farmaceutica

(Get Free Report)

Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, and marketing of pharmaceuticals worldwide. The company operates through Specialty and Primary Care and Rare Diseases segments. Its product pipeline includes REC 0559 which is in Phase II for the treatment of Neurotrophic Keratitis; REC 0545 for acute decompensation in maple syrup urine diseases; ISTURISA for endogenous Cushing's syndrome; and CYSTADROPS, an corneal cystine deposits in patients with cystinosis.

See Also

Receive News & Ratings for Recordati Industria Chimica e Farmaceutica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recordati Industria Chimica e Farmaceutica and related companies with MarketBeat.com's FREE daily email newsletter.